Content available at: https://www.ipinnovative.com/open-access-journals

International Journal of Clinical Biochemistry and Research

Journal homepage: www.ijcbr.in

Review Article

Recent innovations in glycobiology: Biochemical advances and applications

Swapnil Phade[1]*, Dipali Mane[1], Abhijeet Survase[2], Pankaj Khuspe[1], Trushali Madhare[3]

[1]Shriram Shikshan Sanstha, Paniv, Maharashtra, India.

[2]Vidya-Niketan College of Pharmacy, Lakhewadi, Maharashtra, India.

[3]Navsahyadri Institute of Pharmacy, Maharashtra, India.

Abstract

The study of carbohydrates and how they affect boil ogical processes, or glycobiology, has advanced significantly in recent years, transforming a number of industries, including diagnostics, biotechnology, and medicine. Advances in glycobiology have shown the intricate functions of glycans in immunological response, cellular communication, and the development of disease. In addition to improving our comprehension of basic biological processes, these advancements have created new opportunities for therapeutic therapies. Important developments include the creation of synthetic glycans for targeted drug delivery, the use of glycan arrays for high-throughput screening of glycosyl-protein interactions, and developments in glycomics technologies that allow thorough characterization of glcan structures. Furthermore, new biomarkers and therapeutic targets have been found as a result of the integration of glycobiology with genomes, proteomics, and systems biology, especially in the areas of autoimmune disorders, cancer, and infectious illnesses. The potential of glycobiology in healthcare is further demonstrated by the development of glycan-based vaccinations and glyco-engineering techniques to increase the stability and effectiveness of biologics. With an emphasis on the revolutionary effects these developments have had on drug development, illness treatment, and diagnostic tools, this review article attempts to give a broad overview of the most recent advances in glycobiology.

Keywords: Glycobiology, Glycans, Glycomics, Drug delivery, Bio-markers.

Received: 08-12-2024; **Accepted:** 27-02-2025; **Available Online**: 22-03-2025

1. Introduction to Glycobiology

In biochemical and medicinal research, glycobiology the study of glycan structure, production, and function—has become a crucial area of study. Glycans are essential biomolecules that control a variety of biological processes. They are complex carbohydrate compounds that are conjugated to proteins and lipids. These molecules, which result from complex biosynthetic processes controlled by *glycosyltransferases* and *glycosidases*, exhibit enormous structural variation. Since glycans are not directly template-driven like proteins and nucleic acids are, their production is extremely dynamic and sensitive to physiological circumstances. The ability to interpret glycan structures and clarify their functions in physiological and pathological processes has been greatly improved by developments in analytical techniques including mass spectrometry (MS), glycan microarrays, and glycoproteomic. Recent advances in glycobiology have highlighted the interdisciplinary importance of the subject by revealing novel glycan-mediated pathways in immunological regulation, cancer biology, neuroscience, and infectious disease pathogenesis.[1-2]

1.1 Overview of glycobiology and its historical development

The study of glycan structure, function, and production, or glycobiology, has become a crucial area of contemporary biochemistry that interacts with immunology, molecular biology, and biomedical engineering. Complex carbohydrates called glycans, which are covalently bonded to proteins and lipids, are essential for immunological control, cellular communication, and the development of illness. Glycobiology is now at the forefront of therapeutic development, including glycoengineering, biomarker identification, and drug design, thanks to its structural diversity and functional significance. In the past, the significance of carbohydrates was first undervalued,

*Corresponding author: Swapnil Phade
Email: ponicorp@gmail.com

DOI: https://10.18231/j.ijcbr.2025.001

primarily because glycans are more complex and diverse than proteins and nucleic acids.[3] Nonetheless, the fundamental ideas were established by groundbreaking research in the middle of the 20th century, such as the clarification of glycoprotein structures and glycan biosynthesis routes. Important new information about glycan-mediated cell signaling and pathogen-host interactions was made possible by the discovery of lectins, which are proteins that bind glycans specifically. Since then, technological developments have revolutionized glycol-science by enabling high-resolution structural characterization and functional investigation, especially in the areas of mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and glycosyl microarrays.[4-5]

The glycan engineering and therapeutic applications are possible due to advancements in synthetic glycobiology and glycolanalytics. The production of structurally specified glycoconjugates has been made easier by developments in chemoenzymatic synthesis and metabolic glycan labeling, which has improved research on glycan-protein interactions. Furthermore, systems glycobiology has advanced our knowledge of glycan biosynthesis and its regulatory networks by fusing computational modeling and omics technology. Glycans' roles in neurobiology, infectious illnesses, and cancer have drawn more interest recently as new research shows that they may be used as therapeutic targets and diagnostic markers. Nonetheless these developments, difficulties still exist, especially in understanding the intricate connection between glycan structures and their biological roles, or the "glycan code." Novel analytical methods, artificial intelligence-driven glycol-proteomics, and glycan-based precision medicine are promising directions for translational research and clinical applications in glycol-biology.[6-7]

1.2. The importance of glycans in cellular and molecular functions

Glycans are essential for regulating immunological recognition, signal transduction, protein folding, and cellular communication. Precise molecular recognition processes are made possible by their structural complexity, which permits particular interactions with lectins, glycoproteins, and glycolipids. Protein stability, transport, and functional activity are all impacted by post-translational changes like N- and O-glycosylation, which are essential for preserving cellular homeostasis. Pathological situations such as neurodegenerative illnesses, inflammatory disorders, and oncogenesis are characterized by abnormal glycosylation. Changes in glycosylation patterns in cancer influence immune evasion, tumor microenvironment interactions, and cell adhesion, which in turn drives metastasis. Similar to this, host-pathogen interactions are determined by glycosylation changes in viral glycoproteins, which also affect viral entrance and immune evasion tactics. Glycans' medicinal potential is becoming more widely acknowledged, and glycoengineering techniques are transforming precision medicine, vaccine development, and monoclonal antibody therapies. Because of their intrinsic variability and the absence of direct genetic encoding, glycan structure elucidation still faces difficulties despite recent advancements. In order to interpret glycan complexity and open the door to the development of new biomarkers and glycan-targeted treatments, future research will combine artificial intelligence (AI)-driven glycol-informatics, synthetic glycobiology, and sophisticated imaging tools.[8-9]

2. Advancements in Glycomics

With the creation of improved analytical tools, glycomics—the thorough study of glycan structures, production, and functions—has made tremendous strides. Because of their non-template-driven synthesis, glycans are inherently complicated and require specific methods for structural clarification. Glycans, in contrast to proteins and nucleic acids, are highly, micro heterogeneous which makes characterizing them extremely difficult. Nonetheless, high-resolution characterization of glycan structures, their alterations, and their biological interactions is now possible thanks to recent advancements in glycomic technologies. Modern techniques including high-throughput sequencing, glycan microarrays, and mass spectrometry (MS) have transformed glycan study and allowed for a greater understanding of glycan-mediated cellular processes. These developments highlight the critical significance of glycomics in contemporary biomedical research and have significant ramifications for therapeutic glycoengineering, illness diagnostics, and biomarker discovery.[3-4]

2.1. Technologies for glycan analysis: Mass spectrometry, glycan arrays, and high-throughput sequencing

Glycomic analytical tools have advanced dramatically, improving glycan characterization throughput, sensitivity, and accuracy. With its unmatched structural resolution for glycan profiling, MS has become a fundamental method. Glycan composition, linkages, and branching patterns can be precisely clarified using tandem MS in conjunction with matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI). In order to overcome the difficulties caused by isomeric complexity, structural analysis has been further enhanced by recent developments in ion mobility spectrometry and glycan fragmentation techniques. Research on glycan biomarkers has also advanced thanks to integration with liquid chromatography (LC-MS), which has made high-throughput glycomic profiling in biological samples easier.[10] A strong platform for high-throughput research on glycan-ligand interactions is offered by glycosyl microarrays. The immobilized glycans in these arrays enable the systematic screening of lectins, antibodies, and viral glycoproteins, among other glycan-binding proteins. Chemoenzymatic synthesis and microfluidic-based techniques are two recent advancements in microarray construction that have increased the diversity of glycan libraries and enhanced the ability to identify tiny glycan recognition patterns. In order to create targeted therapies, this technology has been crucial in understanding immune recognition, host-pathogen interactions, and glycan changes linked to cancer.[11]

Glycan analysis is increasingly using high-throughput sequencing methods, especially in glycoproteomics and glycoRNA studies. Glycosylation site mapping and glycan structure inference have been made possible at a never-before-seen scale by developments in next-generation sequencing (NGS). New techniques like single-molecule glycol-proteomics and nanopore-based glycan sequencing have the potential to improve the accuracy of real-time glycan analysis. Because glycan structures are inherently variable and lack direct genetic encoding, difficulties in accurately interpreting them still exist despite recent advancements. It is anticipated that advancements in AI-driven glycol-informatics, integrated multi-omics methodologies, and glycol synthetic automation would further advance glycomic research and provide new biological and therapeutic understandings.[12,13]

2.2. Profiling glycan structures and the role of glycans in cellular signaling

Clarifying the various biological roles of glycan structures, especially in cellular signaling, requires thorough profiling of these structures. High-resolution analytical tools including mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, and capillary electrophoresis have significantly advanced glycomics, the systematic study of glycan compositions and their interactions. These techniques provide important insights into glycan-mediated regulatory mechanisms by enabling the analysis of glycan heterogeneity, branching patterns, and post-translational alterations. Recent advancements in MS-based glycoproteomics, such as electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI), have improved the sensitivity and specificity of glycan detection, making it easier to identify disease-specific glycoforms and find biomarkers.[14]

Glycans play a crucial role in cellular signaling, coordinating important functions such immunological regulation, receptor activation, and cell-to-cell communication. Transduction pathways that control cellular responses are started by glycan-mediated interactions with lectins, selectins, and siglecs. According to the cancer biology, abnormal glycosylation modifies receptor signaling, which encourages angiogenesis, tumor growth, and immune evasion. For example, hyper sialylation of glycoproteins on the surface protects cancer cells from immune monitoring, allowing them to spread to other locations. Glycosylation plays a key role in inflammatory disorders and autoimmunity by influencing cytokine activity, T-cell activation, and antigen recognition in immune control. Additionally, host-pathogen interactions are determined by glycosylation changes in viral envelope proteins, which affect immune escape mechanisms and infectivity.[15] Notwithstanding these developments, glycan structural annotation still faces difficulties because of their great diversity and non-template-driven synthesis. To improve the accuracy of glycan profiling, experimental methods are being combined with cutting-edge computational tools like glycoinformatics and machine learning techniques. Future studies will focus on developing standardized glycomic databases, improving glycan sequencing technology, and elucidating the intricate relationship between cellular signaling networks and glycosylation patterns. These developments will speed up the development of biomarkers, precision medicine applications, and glycan-based medicinal approaches.[16]

3. Glycan-Protein Interactions

Many biological processes, such as immunological recognition, cell signaling, and pathogen-host interactions, depend on glycan-protein interactions. Glycan-binding proteins (GBPs), including lectins, selectins, and siglecs, are the main mediators of these interactions. They identify particular glycan patterns and set off subsequent cellular reactions. Glycans' structural variety allows for high-affinity and selective binding, which affects the stability, function, and conformation of proteins. Developments in structural biology and glycomics, such as cryo-electron microscopy and X-ray crystallography, have shed light on the molecular processes that underlie these relationships.[17,18]

Glycan mimetics and glycoprotein-based therapies have been made easier to develop thanks to recent advancements in glycan engineering and synthetic glycobiology. Glycan-protein interactions are used in cancer immunotherapy to improve antitumor immunity and modify immunological checkpoints. Similar to this, new antiviral tactics have been developed in infectious disease research as a result of a better understanding of how viral glycoproteins interact with host receptors. The non-template-driven synthesis and structural heterogeneity of glycans, however, make it difficult to fully decipher the complexity of the glycan interactome. To map glycan-protein networks more thoroughly, experimental techniques are being combined with cutting-edge computational and artificial intelligence (AI)-driven gluco-informatics methodologies. The biomedical applications of these interactions will be further expanded by future developments in precision therapies and glycan-targeted drug design.[19,20]

3.1 Mechanisms of glycan-protein binding and its implications for cellular communication.

Glycan-protein interactions, which mediate molecular recognition, signal transduction, and cellular adhesion, are essential to a wide range of biological processes. Carbohydrate-binding proteins with specificity for different glycan motifs, such as lectins, selectins, siglecs, and galectins, are the main agents that mediate these interactions.

Glycan-protein binding is distinguished by multivalency, in contrast to enzyme-substrate interactions, in which a number of weak affinity connections work together to increase binding strength and specificity. The glycoside cluster effect is a process that is essential for regulating extracellular communication and preserving cellular homeostasis. The capacity to investigate these interactions at molecular resolution has been greatly enhanced by recent developments in glycosyl microarrays, surface plasmon resonance (SPR), and isothermal titration calorimetry (ITC), which have revealed unique glycan-binding signatures pertinent to disease pathophysiology.[21]

In immune response modulation, pathogen identification, and tumor growth, the function of glycan-protein interactions in cellular communication is very clear. Both innate and adaptive immunity are impacted by lectin-glycan recognition, which controls leukocyte trafficking, antigen presentation, and cytokine signaling. To control immune cell activation and avoid excessive inflammatory reactions, siglecs, for example, identify sialylatedglycans. Similarly, leukocyte rolling adherence along endothelium surfaces—a critical step in immune surveillance and inflammation resolution—is mediated by selectins. Changes in glycan landscapes in cancer biology encourage ligand binding to galectins, which in turn drives immune evasion, angiogenesis, and tumor cell adhesion. Furthermore, bacterial and viral infections use glycan-protein interactions to take control of the host's cellular processes; the influenza virus's hemagglutinin attaches to sialylated receptors to determine the host's specificity and contagiousness.[22] Notwithstanding these developments, it is still difficult to understand the dynamic character and structural complexity of glycan-protein interactions. Novel binding processes may be clarified with the help of synthetic glycan libraries, AI-driven modeling, and high-throughput glycoproteomics. Targeting glycan-protein interactions for therapeutic purposes, such as immune checkpoint regulation, glycomimetic drug design, and anti-adhesion tactics for infectious diseases, will be the main focus of future study. These developments will open the door for precision medicine techniques in immunotherapy, cancer, and the treatment of infectious diseases by revealing the complex interactions between glycans and proteins.[23]

3.2 Case studies of glycan-protein interactions in immune response and cancer.

Key pathways such immune cell activation, pathogen detection, and tumor immune evasion are influenced by glycan-protein interactions, which are essential for immunological control and cancer progression. Critical insights into the functional importance and therapeutic potential of these relationships can be gained from case studies. Glycan-lectin interactions are essential for regulating inflammation and pathogen protection in the immune response. The relationship between immune cell Siglec receptors and sialylatedglycans is one well-documented example. As immunological checkpoints, siglecs—a family of immunoglobulin-like lectins that bind sialic acid—transmit inhibitory signals when they recognize glycans. For example, Siglec-10 inhibits macrophage-mediated phagocytosis and aids in immune evasion by binding to CD24, a highly glycosylated protein on tumor cells. One possible immunotherapeutic approach to improve anti-tumor immunity is to target Siglec-CD24 interactions. Similarly, high-mannose glycans on viral glycoproteins are recognized by the C-type lectin receptor dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN), which promotes antigen presentation and adaptive immune activation. In viral infections like HIV and SARS-CoV-2, where glycan shielding tactics allow immunological escape, this glycan-dependent immune regulation is essential.[24]

Changes in glycosylation patterns in cancer influence immune detection, metastasis, and cell adhesion, which in turn drives tumor growth. On the surface of cancer cells, sialylated and fucosylatedglycans are overexpressed, which improves their interactions with selectins and encourages tumor cell extravasation and metastatic spread. The binding of sialyl-Lewis X (sLeX) glycans to endothelial E-selectin is a prominent example. This binding promotes circulating tumor cell adherence to the vascular endothelium, a crucial stage in metastasis. Furthermore, glycosylation of programmed death-ligand 1 (PD-L1) improves its stability and immune checkpoint function, reducing T-cell-mediated cytotoxicity. Glycoengineered monoclonal antibodies and glycosidase inhibitors are two promising preclinical and clinical treatments that try to alter glycan structures in order to break these connections.[25] Despite progress, glycosylation heterogeneity and dynamic production make it difficult to precisely target glycan-protein interactions. In order to create next-generation glycan-targeted immunotherapies and enhance precision medicine techniques in the treatment of infectious diseases and cancer, future research will concentrate on combining glycoproteomics with AI-driven glycan modeling.[26]

4. Applications in Drug Delivery and Therapeutics

4.1 Glycans in drug targeting and delivery systems.

Glycans, which provide selectivity, biocompatibility, and enhanced therapeutic efficacy, have become essential parts of drug targeting and delivery systems. They are crucial for targeted drug delivery, enhancing pharmacokinetics, biodistribution, and cellular absorption due to their capacity to facilitate precise molecular recognition. Drug delivery techniques have been completely transformed by recent developments in glycosylated prodrugs, glycoengineered antibodies, and glycan-based nanocarriers, especially in the fields of infectious illnesses, cancer, and regenerative medicine. Glycans' function in receptor-mediated endocytosis is among their most important uses in drug targeting. Drug delivery specific to the liver is made possible by glycan ligands' selective binding to lectin receptors, such as asialoglycoprotein receptors (ASGPRs) in hepatocytes. Hepatotropic treatments, such as glycosylated nanoparticles intended for targeted siRNA and gene delivery in hepatic diseases, have made use of this strategy. Likewise, mannose or fucose-decorated glycan-functionalized liposomes target dendritic cell lectins, improving antigen delivery for vaccine development. This tactic reduces systemic toxicity while enhancing immunological activation.[27]

Glycoengineered monoclonal antibodies maximize their anti-tumor activity in cancer treatments by utilizing Fc-glycosylation modifications to improve complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Furthermore, glycan-based tumor-homing techniques take use of cancer cells' overexpressed glycan-binding receptors, like Siglecs and galectins. By reducing off-target effects, nanoparticles coupled with sialylated or fucosylated glycans improve tumor penetration and selective drug release. Additionally, recent research has shown that glycosylated prodrugs increase drug solubility and metabolic stability, extending the duration of circulation and slowing down fast clearance. Notwithstanding these developments, problems with glycan stability, heterogeneity, and large-scale synthesis for therapeutic uses still exist. To improve glycan-based drug delivery systems, future studies will combine artificial intelligence (AI)-driven glycol-informatics, synthetic glycobiology, and sophisticated glycan engineering. Targeted therapies will be further refined by developments in glycan-responsive nanocarriers and bio orthogonal glycan alterations, creating new opportunities for precision medicine and individualized treatment plans.[28,29]

4.2 Glyco-engineering of biologics for improved stability and efficacy

A potent technique for enhancing the pharmacokinetics, stability, and effectiveness of biologic therapies, such as vaccinations, recombinant proteins, and monoclonal antibodies (mAbs), is glyco-engineering. Researchers hope to improve therapeutic efficacy, lower immunogenicity, and increase serum half-life by carefully altering glycan architectures. Since glycosylation affects immunological interactions, receptor binding, and protein folding, logical glyco-engineering techniques have proved crucial in enhancing biologic medication compositions. Optimizing the Fc glycosylation of therapeutic antibodies to alter effector activities is one of the main uses of glyco-engineering. For instance, IgG antibodies' core focus on the Fc region lowers their binding affinity to the Fc gamma receptor IIIa (FcγRIIIa), which in turn lessens antibody-dependent cellular cytotoxicity (ADCC). Obinutuzumab and mogamulizumab, have been developed to increase the anti-tumor efficacy of ADCC. Similarly, using glycan-mediated immunosuppressive effects, sialylation of the Fc domain has been investigated to create anti-inflammatory mAbs with decreased immune activation.[30]

Enhancing the solubility and resistance to proteolysis of therapeutic proteins is another important function of glyco-engineering. This strategy is demonstrated by recombinant erythropoietin (EPO), which is used to treat anemia. Hyperglycosylation prolongs its circulatory half-life, which lowers the frequency of doses and improves patient compliance. Glyco-engineering has been used to optimize mannose-6-phosphate (M6P) tagging in enzyme replacement therapies, such as recombinant α-glucosidase for Pompe illness, guaranteeing effective lysosomal targeting and therapeutic efficiency. Glyco-engineered antigens have been used in vaccine development to increase stability and immunogenicity. Glycoconjugate vaccines have proven to be very successful in preventing bacterial infections because they contain pathogen-specific glycans conjugated to carrier proteins. Furthermore, the development of next-generation antiviral vaccines with improved immune recognition has been investigated through the integration of specific glycan epitopes into viral glycoproteins.[31,32] The intricacy of glycosylation pathways makes it difficult to achieve accurate and repeatable glycan changes, even with major breakthroughs. The next generation of biotherapeutic advancements may benefit from the combination of glycoengineering, CRISPR-based genome editing, glycosylation pathway reprogramming, and AI-driven glycan design. Glycan-based drug delivery techniques will be further refined in future studies, and biologic treatments will be optimized for increased stability, efficacy, and safety.[33]

4.3 Glycan-based vaccines and therapeutic antibodies

By utilizing the distinct structural characteristics of glycans to improve immunogenicity and therapeutic efficacy, glycan-based vaccines and therapeutic antibodies have become revolutionary instruments in immunotherapy and the prevention of infectious diseases. The development of glycoengineered monoclonal antibodies (mAbs) and carbohydrate-based vaccine platforms has been fueled by the complex function of glycans in immune recognition, providing new approaches to targeted disease intervention. Glycan-Based Vaccines: Especially for bacterial and viral illnesses, the immunogenic potential of pathogen-associated glycans has been widely utilized in vaccine development. Immune responses against encapsulated bacteria, including Streptococcus pneumoniae and Neisseria meningitidis, have been markedly enhanced by conjugate vaccines, which involve microbial polysaccharides covalently bound to immunogenic protein carriers.[34,35] These vaccines overcome the drawbacks of pure polysaccharide vaccines by generating strong T-cell-dependent antibody responses. As demonstrated in the cases of HIV and SARS-CoV-2, glycan-mimetic antigens have been investigated in the creation of viral vaccines in order to produce neutralizing antibodies against glycosylated viral envelope proteins. The exact tailoring of carbohydrate antigens has been made possible by developments in synthetic glycobiology, improving the stability and immune specificity of vaccines. In order to increase the effectiveness of vaccines, new adjuvant techniques have been developed that incorporate glycan ligands for pattern recognition receptors (PRRs), such as Toll-like receptor agonists.[36,37]

Glycoengineered Therapeutic Antibodies: A key component of contemporary biopharmaceuticals are monoclonal antibodies, and one important tactic to maximize their therapeutic efficacy is glycoengineering. The two primary processes that underpin mAb-based immunotherapy, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), are significantly impacted by the glycosylation of the Fc domain. For example, the effectiveness of ADCC against cancer cells is increased by afucosylatedm Abs, which show improved binding to the Fcγ receptor IIIa (FcγRIIIa). The invention of next-generation anti-CD20 mAbs for B-cell malignancies, including obinutuzumab, which has better cytotoxic action than traditional rituximab, has effectively used this idea. Similarly, therapeutic mAbs for autoimmune diseases are investigating the modulation of anti-inflammatory effects through sialylation of Fc glycans. Due to the intrinsic heterogeneity of glycosylation pathways in mammalian expression systems, difficulties in producing homogenous glycan structures on a wide scale still exist despite these developments. These restrictions may be overcome by new glycoengineering methods like cell-free glycoprotein production and CRISPR-based glycosylation editing. Future studies will concentrate on combining artificial intelligence with glycan profiling to improve vaccination and antibody design, opening the door for more accurate and effective next-generation glycan-based immune-therapeutics.[38,39]

5. Glycobiology in Disease Mechanisms

5.1. The role of glycans in infectious diseases, autoimmune disorders, and cancer.

Glycans are key players in the pathophysiology of disease, affecting immune regulation, host-pathogen interactions, and malignant transformation. They are important factors in the development of autoimmune illnesses, infectious diseases, and cancer because of their structural variety and functional specialization. Significant improvements in illness diagnosis and treatment approaches have resulted from an understanding of glycan-mediated processes. Glycans in Infectious

5.2. Diseases

Pathogenic microbes use the glycan structures of their hosts to adhere to them, evade the immune system, and enter cells. Hemagglutinin in influenza and the spike protein in coronaviruses are examples of viral envelope glycoproteins that interact with host sialic acid receptors to mediate infection. Immune escape is made possible by glycan shielding, which is shown in HIV and SARS-CoV-2 and involves extensive glycosylation to cover antigenic epitopes. As demonstrated by Helicobacter pylori's interaction with Lewis's antigens in the gastric epithelium, bacterial pathogens also use glycan-binding adhesins to invade host tissues. Furthermore, malaria-related alterations in red blood cell surface glycans promote cytoadherence and immunological regulation, while parasite infections like Plasmodium falciparum depend on glycan modifications to avoid immune detection. With glycomimetic inhibitors and glycan-based vaccines demonstrating encouraging outcomes, targeting pathogen-glycan interactions has become a feasible approach for antiviral, antibacterial, and antiparasitic treatments.[40,**Error! Reference source not found.**]

Glycans in Autoimmune Disorders: By changing antigen presentation, cytokine signaling, and antibody activity, aberrant glycosylation plays a role in immunological dysregulation in autoimmune illnesses. Hypogalactosylation of immunoglobulin-G (IgG) Fc glycans in rheumatoid arthritis increases joint inflammation by promoting pro-inflammatory signaling through Fcγ receptor binding. Similar to this, elevated autoantibody sialylation in systemic lupus erythematosus alters how these antibodies interact with immune complexes, thereby influencing the severity of the disease. Autoimmune activation results from glycoprotein glycosylation defects that affect T-cell tolerance and self-antigen recognition, such as in MHC class II molecules. To restore immune homeostasis and slow the progression of disease, researchers are investigating new developments in glycan-targeted therapies, such as glycoengineered antibodies and glycosidase inhibitors. Glycans in Cancer: By modifying cell adhesion, immunological recognition, and signaling pathways, tumor-associated glycosylation changes promote oncogenesis. Through selectin-mediated adhesion, hypersialylation of glycoproteins, including mucins, produces a glycan-rich shield that shields tumor cells from immune attack and increases their potential to spread. Growth factor receptor signaling is impacted by aberrant fucosylation and branching of N-glycans, which encourages tumor growth and apoptosis resistance. Furthermore, as demonstrated by the glycosylation of programmed death-ligand 1 (PD-L1), which increases its stability and suppressive activity, glycan changes control immunological checkpoint pathways. While glycoimmunotherapy techniques, such as glycoengineered monoclonal antibodies and cancer vaccines, show promise for targeted therapy, glycan-based biomarkers, including sialyl-Tn antigen, are being used for cancer diagnosis.[41,42]

Despite these developments, the structural heterogeneity and dynamic production of glycans make it difficult to fully understand the mechanisms underlying glycan-mediated illness. To further precision medicine techniques, it will be essential to integrate glycoproteomics, glycoinformatics, and machine learning-based glycan modeling. In order to treat cancer, autoimmune illnesses, and infectious diseases with greater effectiveness and fewer side effects, future research will concentrate on creating highly specific glycan-targeted therapies.[43,44]

5.2 Glycan biomarkers for early diagnosis and prognosis.

Glycans are essential to the pathophysiology of disease, and changes in their structure are frequently used as early warning signs of pathological conditions. In oncology, neurological illnesses, and infectious diseases in particular, the identification of glycan biomarkers has greatly improved diagnostic and prognostic approaches. Aberrant glycosylation patterns can reflect disease onset, progression, and therapeutic response, making glycans valuable molecular signatures for precision medicine applications. In cancer diagnostics, glycan-based biomarkers have gained prominence due to their high specificity and sensitivity. Tumor-associated carbohydrate antigens (TACAs), such as sialyl Tn (sTn) and Lewis's antigens, are frequently overexpressed in malignancies and serve as key indications of tumor progression. For instance, alpha-fetoprotein-L3 (AFP-L3), a fucosylated form of AFP, is commonly utilized for the early identification of hepatocellular carcinoma, distinguishing malignant from benign liver diseases. Similarly, carbohydrate antigen 19-9 (CA19-9) serves as a diagnostic marker for pancreatic cancer, enabling in early intervention and disease surveillance. Advances in glycoproteomics and high-throughput glycan analysis have further simplified the identification of novel glycosylation signatures, enhancing early detection capabilities.[45,46]

The **Table 1** shows Glycobiology Applications in Disease Management and Personalized Medicine.

Table 1: Glycobiology applications in disease management and personalized medicine[41-45]

Application	Role of Glycans	Future Potential
Cancer Diagnosis & Therapy	Aberrant glycosylation patterns serve as biomarkers; glycoengineered immunotherapies enhance targeting.	Personalized glycan-based therapies and glyco-immune modulation for precision oncology.
Neurodegenerative Diseases	Glycan alterations impact protein aggregation, neuroinflammation, and synaptic function.	Glycan-targeted drugs for Alzheimer's and Parkinson's, focusing on disease-modifying treatments.
Infectious Disease Control	Pathogens utilize glycans for host-cell entry; glycan-based vaccines improve immune response.	Development of synthetic glycan-based antivirals and next-gen vaccines.
Autoimmune & Inflammatory Disorders	Glycan-protein interactions modulate immune activation and tolerance.	Glycan-engineered biologics to regulate immune pathways and reduce inflammatory responses.
Regenerative Medicine & Drug Delivery	Glycans influence stem cell differentiation, biomaterial biocompatibility, and targeted drug delivery.	Glyco-functionalized biomaterials and smart drug delivery systems for tissue engineering.

Table 2: Technological challenges and future prospects in glycobiology research.

Challenge	Description	Future Prospects
Glycan Structural Complexity	Glycans exhibit high heterogeneity with isomeric and branching variations, complicating analysis.	Advanced glycan sequencing, nanopore technology, and improved mass spectrometry methods.
Analytical Limitations	Existing tools like MS and NMR require extensive expertise and are labor-intensive.	AI-driven computational tools and automation in glycomics workflows.
Lack of Glycan-Specific Reagents	Limited availability of high-affinity antibodies and lectins for glycan targeting.	Development of synthetic glycan libraries, engineered glycan-binding proteins, and glycan microarrays.
Computational Bottlenecks	Limited predictive models for glycan functions and interactions.	AI/ML integration with glycomics for better glycan annotation and predictive modeling.
Translational Barriers	Slow transition from fundamental glycol science to clinical applications.	Interdisciplinary collaboration to bridge glycobiology with synthetic biology, nanotechnology, and bio pharma.

Glycan biomarkers have been linked to neurodegenerative diseases like Alzheimer's disease (AD) in addition to oncology. Amyloid aggregation and the formation of neurofibrillary tangles, two characteristics of AD pathology, are facilitated by altered glycosylation of tau and amyloid precursor protein (APP). Certain glycan alterations in cerebrospinal fluid (CSF) proteins have been shown in recent research to have diagnostic potential, providing non-invasive indicators for early illness diagnosis. Furthermore, pathogen-induced glycan modification can be used as a diagnostic tool in infectious illnesses. For instance, alterations in serum glycosylation patterns during viral infections, like influenza and SARS-CoV-2, have been connected to the severity of the disease and the modulation of the immune response.[47] There are also issues with the clinical translation of glycan biomarkers, despite their encouraging potential. For precise profiling, sophisticated analytical methods such as mass spectrometry and glycosyl microarrays are required due to the structural complexity and heterogeneity of glycans. Furthermore, in order to guarantee reliability in various clinical contexts, glycan-based diagnostic assays must be standardized. In order to improve predictive accuracy and individualized diagnostic approaches, future research will concentrate on combining the identification of glycan biomarkers with machine learning-driven data analysis. Glycomics' ongoing development in illness diagnostics has enormous potential to enhance prognosis and early identification, which will ultimately improve patient outcomes.[48]

6. Future Directions and Challenges.

6.1 The need for integrating glycobiology with genomics and systems biology.

Glycobiology, genomics, and systems biology must be integrated due to the intricacy of glycan structures and their wide-ranging roles in cellular and molecular processes. Glycans' biosynthesis is extremely dynamic and context-dependent because, in contrast to proteins and nucleic acids, they are not directly templated by the genome. This structural and functional variety complicates glycosyl analysis and needs a multi-omics approach to interpret glycan-mediated biological activities thoroughly. By integrating glycomics with genomic, transcriptomic, and proteomic data, researchers can uncover functional linkages between glycosylation patterns and disease phenotypes, paving the path for innovative therapeutic and diagnostic breakthroughs.[49]

Recent developments in next-generation sequencing and genome-wide association studies (GWAS) have revealed genetic determinants of glycosylation, providing insight into the regulation of glycan production by certain glycosyltransferases and glycosidases. Congenital disorders of glycosylation (CDGs), for instance, have been linked to abnormalities in the genes encoding glycosylation enzymes, highlighting the significance of genomic insights in comprehending glycan associated diseases. Furthermore, the characterization of cell type specific glycosylation profiles is made possible by the combination of glycobiology with single-cell transcriptomics, providing a more sophisticated comprehension of glycan heterogeneity in healthy and pathological settings.[50,51]

Using systems biology techniques like network analysis and computational modeling improves our comprehension of intricate glycan interactions. AI and machine learning are used in systems glycobiology to forecast glycan activities, find new disease biomarkers linked to glycosylation, and improve glycoengineering techniques for the creation of biopharmaceuticals. The regulatory pathways controlling glycan production and its interactions with cellular signaling networks can be clarified by combining high-throughput glycomics data with metabolic modeling powered by bioinformatics. Determining the function of glycans in immunological regulation, neurological disorders, and cancer—where glycosylation changes impact the course of disease—requires an integrative approach.[52]

Notwithstanding these developments, standardizing glycomics techniques and combining diverse datasets from various biological scales continue to present formidable obstacles. One of the main obstacles to multi-omics research is the intrinsic complexity of glycan structures and the absence of widely used analytical platforms. Furthermore, in order to handle the enormous structural diversity of glycans, glycan databases and computational tools need to be continuously improved. Developing reliable glycome-wide association studies (GWA studies), enhancing mass spectrometry-based glycan profiling, and honing AI-driven glycan annotation systems should be the main goals of future research. Integrating glycobiology with genomics and systems biology has the potential to lead to revolutionary breakthroughs in biotechnology and biomedicine by promoting interdisciplinary cooperation among glycobiologists, bioinformaticians, and systems biologists.[53]

6.2 Technological challenges and future prospects in glycobiology research.

Glycobiology research has made amazing gains in recent years, although considerable technological difficulties exist, impeding the full exploitation of glycan functionalities in biological systems. The intricacy of glycan structures, their dynamic production, and their context-dependent biological activities present severe challenges in unraveling glycan-mediated pathways. Glycans, in contrast to proteins and nucleic acids, are not directly templated by the genome, which results in significant heterogeneity and necessitates the use of advanced analytical techniques for structural clarification.[2,3,54]

A brief overview of technological challenges and future prospects in glycobiology research is provided in **Table 2**. Advances in glycemic techniques, computational modeling, and high-throughput analytical platforms are necessary to meet these obstacles and hasten glycobiology discoveries. The absence of widely accepted, high-resolution analytical methods for thorough glycan profiling is one of the main obstacles to glycobiology research. The gold standards for characterizing glycans are still mass spectrometry and nuclear magnetic resonance spectroscopy, however these techniques are frequently time-consuming, necessitating a great deal of sample preparation and data interpretation skills. Furthermore, data collection is made more difficult and automation in glycomic investigations is restricted by the intrinsic structural complexity of glycans, which includes isomeric variances and branching patterns. Nanopore-based technologies and sophisticated MS-based processes that use ion mobility spectrometry are examples of recent advancements in glycan sequencing that show promise for increasing throughput and accuracy.[55]

The scarcity of glycan-specific instruments, like as lectins and monoclonal antibodies, which are crucial for researching glycan-protein interactions, is another urgent issue. Targeted research into glycan-mediated signaling pathways has been made easier by the creation of synthetic glycan libraries, glycosyl microarrays, and modified glycan-binding proteins. However, because enzymatic and chemical synthesis methods are so complicated, producing structurally defined glycans is still a time-consuming procedure. It is anticipated that developments in automated glycan assembly and chemoenzymatic synthesis would provide access to well-defined glycan structures, facilitating more accurate functional analyses.[56]

With machine learning (ML) and artificial intelligence (AI) playing critical roles in glycan structure prediction and function annotation, computational glycobiology is becoming a vital topic for overcoming analytical bottlenecks. Deeper understanding of the systems-level effects of glycans will be possible by combining glycomics data with systems biology methodologies and omics platforms like glycoproteomics and glycan-metabolomics. To promote data integration and enable predictive modeling of glycan activities in health and illness, however, strong glycan informatics tools and databases must be developed.[57,58]

Future developments in therapeutic glycan applications, biomarker identification, and precision medicine could be greatly aided by the confluence of glycomics with synthetic biology, bioengineering, and nanotechnology. Drug design is expected to undergo a revolution with the use of glycoengineering in biopharmaceutical development, especially in glycan-based vaccines and therapeutic antibodies. However, interdisciplinary cooperation and a significant investment in research infrastructure are needed to close the gap between basic glycol science and translational applications. The future of glycobiology holds the possibility of revealing the enormous potential of glycans in biomedicine and biotechnology by tackling these technological obstacles and utilizing state-of-the-art discoveries.

7. Conclusion

Glyco biology has a significant impact on immunological control, disease processes, and cellular communication in contemporary biotechnology and medicine. Precise glycan profiling has been made possible by developments in glycomics, glycoproteomics, and glycoengineering. This has increased therapeutic efficacy, targeted therapy, and early illness diagnosis. While glycoengineered medicines, such as vaccines and monoclonal antibodies, are improving treatment precision in infectious diseases, cancer, and neurological disorders, glycan-based biomarkers are transforming diagnostics. The integration of AI-driven bioinformatics and high-throughput glycan analysis holds promise for the future of glycol-biology in advancing personalized medicine. Next-generation treatments, regenerative medicine, and immunotherapies customized for specific glycol-signatures will be fueled by advancements in synthetic glycol-biology and glycol-engineering. Nevertheless, the difficulties associated with standardization and structural complexity, interdisciplinary cooperation and technical developments will drive glycobiology toward revolutionary discoveries that will influence the development of precision medicine and biopharmaceuticals in the future.

8. Source of Funding

None.

9. Conflict of Interest

None.

References

1. Gagneux P, Hennet T, Varki A. Biological Functions of Glycans. In: Varki A, Cummings RD, Esko JD. Essentials of Glycobiology [Internet]. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. Chapter 7. Available from: https://www.ncbi.nlm.nih.gov/books/NBK579984
2. Reily, C. Glycosylation in health and disease. Nature reviews. *Nephrology*.2019;15(6):346–66.
3. Varki A. Biological roles of glycans. *Glycobiology*.2017;27(1):3–49.
4. Varki A, Kornfeld S. Historical Background and Overview. In: Varki A, Cummings RD, Esko JD., editors. Essentials of Glycobiology.4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK579927
5. Cho, S.H., Park, J.-y., & Kim, C.H. Systemic Lectin-Glycan Interaction of Pathogenic Enteric Bacteria in the Gastrointestinal. *Tract Int J Mol. Sci.*2022;23(3):1451.
6. Dicker, M. Using glyco-engineering to produce therapeutic proteins. Expert opinion on bio. *Ther.*2015;15(10):1501–16.
7. Seeberger PH, et al. Chemical and Enzymatic Synthesis of Glycans and Glycoconjugates. In: Varki A. Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 49. p-130
8. Gagneux P, editors. Essentials of Glycobiology [Internet]. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. Chapter 7. Available from: https://www.ncbi.nlm.nih.gov/books/NBK579984/ doi: 10.1101/glycobiology.4e.7
9. Hassan, S. Glycoprotein- and Lectin-Based Approaches for Detection of Pathogens. Pathogens.2020; 9(9) 694.
10. Alley W. R., Novotny M. V., Structural glycomic analyses at high sensitivity: a decade of progress. *Ann Rev Analyt Chemi*. 2013; (Palo Alto, Calif.), 6, 237–65.
11. Zhang, L. The use of lectin microarray for assessing glycosylation of therapeutic proteins. mAbs,2016;8(3):524–35.
12. Cindrić A., Pribić T., Lauc G. High-throughput N-glycan analysis in aging and inflammaging: State of the art and future directions. *Semin Immunol.*2024*;*73(3):101890.

13. Chen S. Y., Clark D. J., Zhang H. High-Throughput Analyses of Glycans, Glycosites, and Intact Glycopeptides Using C4-and C18/MAX-Tips and Liquid Handling System. *Curr Prot.* 2021; 1(7):e186.
14. Mulloy B. Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 47. p-110-6
15. Gao Y. Role of Glycans on Key Cell Surface Receptors That Regulate Cell Proliferation and Cell Death. *Cells*.2021;10(5):1252.
16. Perez, S. Glycosaminoglycans: What Remains to Be Deciphered?. *JACS Au*. 2023; 3(3):628–56.
17. Taylor ME, Drickamer K, Imberty A. Discovery and Classification of Glycan-Binding Proteins. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. Chapter 28. Available from: https://www.ncbi.nlm.nih.gov/books/NBK579947.
18. Schnaar R.L. Glycans and glycan-binding proteins in immune regulation: A concise introduction to glycobiology for the allergist. *J Aller Clin Immunol*. 2015;135(3):609–15.
19. Anderluh, M. Emerging glyco-based strategies to steer immune responses. *FEBS J*. 2021;(16):4746–72.
20. Hudak J. E., Bertozzi C. R. Glycotherapy: new advances inspire a reemergence of glycans in medicine. *Chem Biol*. 2014;21(1):16–37.
21. He M., Zhou X. Wang X. Glycosylation: mechanisms, biological functions and clinical implications. *SigTransduc Ther*. 2024;9(1):194.
22. Pinho, S. S. Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection. *Cellular Mol Immunol*. 2023; 20(10):1101–13.
23. Nieto-Fabregat, F. Computational toolbox for the analysis of protein–glycan interactions. *Beilstein J Organic Chem.* 2024;20: 2084–107.
24. Wolfert, M. A., Boons, G. J. Adaptive immune activation: glycosylation does matter. *Nat Chem Biol.* 2023;9(12):776–84.
25. Bellis SL. editors. Essentials of Glycobiology [Internet]. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. Chapter 47. Available from: https://www.ncbi.nlm.nih.gov/books/NBK579911/
26. Diniz, F. Glycans as Targets for Drug Delivery in Cancer. *Cancers*. 2014;14(4): 911.
27. Yan S. Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. *Pharmaceutics.* 2024;16(2):248.
28. Kurogochi M. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for Fcγ RIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities. *PloS one*. 2015; 10(7):e0132848.
29. Zhang Y., Fan C., Zhang L., Ma X. Glycosylation-dependent antitumor therapeutic monoclonal antibodies. *Prog Mol Biol Transl Sci*. 2019;163(2)471–85.
30. Solá, R. J. Griebenow, K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. Bio Drugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2010; 24(1):9–21.
31. Sinclair A. M., Elliott S. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. *J Pharma Sci.* .2005;94(8):1626–35.
32. Chen B. Impact of N-Linked Glycosylation on Therapeutic Proteins. *Molecules*. 2022;27(24):8859.
33. Narimatsu Y. Genetic glycoengineering in mammalian cells. *J Biol Chem*. 2022; 296,100448.
34. Martina C. E., Crowe J. E., Meiler J. Glycan masking in vaccine design: Targets, immunogens and applications. *Front Immunol.* 2023;141126034.
35. Berois N., Pittini A., Osinaga E. Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. *Cancers*. 2022;14(3):645.
36. Anderluh M. Recent advances on smart glycoconjugate vaccines in infections and cancer. *FEBS J*. 2022;289(14):4251–303.
37. Kyriakidis N. C. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *NPJ Vaccines.* 2021;6(1):28.
38. Li S., McCraw. Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. Antibodies (Basel, Switzerland). 2021; 10(4):44.
39. Wang, L. X. Glycoengineering of Antibodies for Modulating Functions. *Ann Rev Biochem.*2019;88 433–59.
40. Maverakis E. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. *J Autoimm*. 2015;57:1–13.
41. Flevaris K., Kontoravdi, C. Immunoglobulin G N-glycan Biomarkers for Autoimmune Diseases: Current State and a Glycoinformatics Perspective. *Int J Mol Sci*. 2022 23(9):5180.
42. Zhou, X. Antibody glycosylation in autoimmune diseases. *Autoimmun Rev*. 2021; 20(5):102804.
43. Li H., Chiang A. W. T., Lewis N. E. Artificial intelligence in the analysis of glycosylation data. *Biotech Adv*.2022;60:108008.
44. Riley, N. M., Bertozzi, C. R., & Pitteri, S. J. A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry-Based Glycoproteomics. *Mol Cell Proteom*: MCP, 20:100029.
45. Reily C. Glycosylation in health and disease. *Nature Rev. Nephrol*. 2019;15(6):346–66.
46. Ruhaak L. R. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell Prot: 2013;12(4):846–55.
47. Gholap A. D. Proteomics in oncology: Retrospect and prospects. In Novel Technologies in Biosystems, *Biomed Drug Deliv*.2023;18(2)L243–69.
48. Haukedal, H., & Freude, K. K. Implications of Glycosylation in Alzheimer's Disease. *Front Neurosci*. 2021;14:625348.
49. Reily C. Glycosylation in health and disease. *Nat Rev Nephrol.* 2019;15(6):346–66.
50. Joshi H.J. Glycosyltransferase genes that cause monogenic congenital disorders of glycosylation are distinct from glycosyltransferase genes associated with complex diseases. *Glycobiol*. 2018;28(5):284–94.
51. Ng B.G. Perspectives on Glycosylation and Its Congenital Disorders. *Trends Gen*: TIG, 2018;34(6):466–76.
52. Bojar D., Powers R.K., Camacho D. M., Collins J. J. Deep-Learning resources for studying Glycan-Mediated Host-Microbe interactions. *Cell Host Microbe.*2020;29(1):132-44.e3.
53. Kunej T. Rise of Systems Glycobiology and Personalized Glycomedicine: Why and How to Integrate Glycomics with Multiomics Science? Omics: *J Integrat Biol,* 2019; 23(12), 615–22.
54. Mahara, G. Breakthrough of glycobiology in the 21st century. Front Immunol, 2013;13:1071360.
55. Trbojević-Akmačić, I. High-Throughput glycomic Methods. *Chem Rev.* 2022;122(20):15865–913.
56. Cummings RD. Essentials of Glycobiology. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022.
57. Pace A. Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma. *Int J Mol Sci*. 2022;23(11):6312.
58. Seeberger PH. Glycans in Biotechnology and the Pharmaceutical Industry. In: Varki A, Cummings RD, Esko JD., editors. Essentials of Glycobiology. 4th edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022.

Cite this article: Phade S, Mane D, Survase A, Khuspe P, Madhare T. Recent innovations in glycobiology: Biochemical advances and applications. *Int J Clin Biochem Res.* 2025;12(1):1-10.